

03rd November 2022

The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 The Secretary,
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra East,
Mumbai 400 050

Sub: Changes in Board of Directors

Dear Sirs,

Pursuant to the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has received a letter, from Mr. Charles Billard stating that due to personal reasons he would like to resign as the Non-Executive Director of the Company with effect from 3rd November 2022. The said letter was noted by the Board of Directors at its meeting held today i.e., 3rd November 2022.

Accordingly, Mr. Charles Billard will cease to be the Non-Executive Director of the Company with effect from the close of business hours on 3rd November 2022. The Company and the Board places on record its appreciation for the contribution made by Mr. Charles Billard during his tenure as Director of the Company.

We also wish to inform you that at the said Board Meeting, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ms. Annapurna Das (DIN: 08634664) as an Additional and Non-Executive (Non-Independent) Director of the Company with effect from 3rd November 2022, subject to the approval of the Members of the Company through Postal Ballot.

The Board of Directors seek to ensure an appropriate balance in its composition. In particular, the Board seeks to ensure gender balance and a broad diversity of backgrounds and experience.

Further, in terms of SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015, read with Regulation 30 of the Listing Regulations, her brief profile is enclosed as 'Annexure-I' to this letter.

Please take the above information on record.

Thanking you,

Yours sincerely, **SANOFI INDIA LIMITED**

RADHIKA SHAH
COMPANY SECRETARY & COMPLIANCE OFFICER

Annexure - I

Brief Profile of Ms. Annapurna Das



Annapurna is the Head of Asia, Sanofi Vaccines since June 2022 with responsibility for commercial operations for countries across Asia including India. Prior to this, she was General Manager, Sanofi Vaccines, India since Nov 2019. She has completed her Bachelor's in Science (Chemical Engineering), BIT Sindri and her MBA, Marketing, Madurai Kamraj University.

Annapurna joined Sanofi India in November 2019, after a successful career in major pharmaceutical organizations in India holding roles with increasing responsibilities across sales, marketing, and strategy and business development. Annapurna with more than 23 years of experience, brings to the Company, strong knowledge of the pharmaceutical industry and an energetic drive towards growth and transformation. She has demonstrated in her most recent experience, leading India vaccines organization through a major go to market model transformation, the ability to engage internally and externally, together with a strong resilience. She is a compassionate leader with focus on talent and people development while driving diversity and building an inclusive workplace.

With deep and diverse strategic and operational experience in the pharmaceutical industry in India and other markets across Asia, she has worked across disease and therapeutic areas. Annapurna has led P&L across both pharma and vaccine businesses in India and South Asia markets in leading global pharma companies. Her critical experiences are in life cycle and growth management of mature portfolio, new launches, business model transformation, digital acceleration and establishing innovative partnerships for expanding patient access.

Ms. Annapurna Das is not related to any of the Directors of the Company personally, financially or otherwise and is not debarred or disqualified from being appointed or continuing as director of companies by SEBI / Ministry of Corporate Affairs or any such statutory authority.